- Bay Area Times
- Posts
- Lilly's donanemab slows Alzheimer's by 35% in early-stage patients
Lilly's donanemab slows Alzheimer's by 35% in early-stage patients
Bay Area Times
July 18, 2023
Brought to you by:
Hey, welcome to today's Bay Area Times daily newsletter. If you haven't yet already, follow us on Twitter and on Threads!
Top stories today:
1. Alzheimer's: Lilly's drug slows disease by 35% in early-stage patients
2. U.S. plans to restrict some technology investments in China
3. Microsoft granted 2-month trial pause to negotiate Activision deal with UK
4. Threads announces rate limits, citing spam
0. Data and calendar
All values as of 6 AM ET / 3 AM PT, other than S&P500 close (4 PM ET / 1 PM PT).
All times are ET.
